The FDA has approved concizumab-mtci, a daily subcutaneous treatment to reduce bleeding for patients with hemophilia who have clotting factor inhibitors.
Crinecerfont, a first-in-class therapy, improved androgen control and reduced reliance on high-dose glucocorticoids for patients with congenital adrenal hyperplasia.
The efficacy and safety of several medications have been examined for treating COVID-19 infections of varying severity. Do you know which medication therapies are currently recommended for use in...
Does the clinical practice guideline from the Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association recommend using biophysical agents for managing patellofemoral pain? Take...
In an interview with Consultant360, Kasia Rothenberg, MD, PhD, a geriatric psychiatrist at the Cleveland Clinic Lou Ruvo Center for Brain Health, described the challenges caregivers or family members face...
In an interview with Consultant360, Paul B. Rosenberg, MD, discussed his team’s research on using dronabinol, a legal form of synthetic THC, to treat agitation in patients with Alzheimer disease. What...
Researchers report on the first safety and efficacy of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody, for patients with relapsed/refractory Mantle cell lymphoma. This study was presented at...
